Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
297 hedge funds and large institutions have $4.36B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2019 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 108 increasing their positions, 82 reducing their positions, and 25 closing their positions.
236% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 25
74% more call options, than puts
Call options by funds: $43.6M | Put options by funds: $25.1M
50% more capital invested
Capital invested by funds: $2.91B → $4.36B (+$1.45B)
32% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 82
24% more funds holding
Funds holding: 239 → 297 (+58)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$76.8M |
| 2 |
HM
HealthCor Management
New York
|
+$47.2M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$46.1M |
| 4 |
Renaissance Technologies
New York
|
+$42.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$60.8M |
| 2 |
JP Morgan Chase
New York
|
-$18.1M |
| 3 |
Two Sigma Investments
New York
|
-$14.8M |
| 4 |
PC
Paulson & Co
New York
|
-$11.8M |
| 5 |
PCM
Penserra Capital Management
Orinda,
California
|
-$10.5M |
HZNP Hedge Fund Activity: Q1 2019 in Review
297 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q1 2019, worth a combined $4.36B — up 50% from $2.91B a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new HZNP positions and 25 closed out — a net gain of 59 holders — while 108 added to existing stakes and 82 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $76.8M. The largest seller was Scopia Capital Management, cutting an estimated $60.8M.
- 297 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q1 2019, up from 239 in Q4 2018.
- Funds reported $4.36B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q1 2019, up 50% quarter-over-quarter.
- 84 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q1 2019 and 25 closed out, a net change of +59 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q1 2019 was Fidelity Investments, an estimated $76.8M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q1 2019 was Scopia Capital Management, an estimated $60.8M sold.
Based on aggregated 13F filings for Q1 2019.